Product Information
SYNTHROID 300 MCG TABLET is a brand product labeled by AbbVie Inc., priced at $1.6566 per EA under NDC 00074714990. Its NADAC has been published 671 times since Nov 28, 2013.
FDA first approved this application on Jul 24, 2002. Its Orange Book therapeutic-equivalence code is AB1,AB2 — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
300 ug/1
Manufacturer
AbbVie Inc.NDC
00074714990
Classification
Brand
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
LEVOTHYROXINE SODIUMApproval Type
New Drug (NDA)
FDA Application
NDA021402FDA Approved
7/24/2002
TE Code
AB1,AB2
On Market Since
7/24/2002
Pharmacological Classes
Price Statistics
The NADAC for SYNTHROID 300 MCG TABLET has been published 671 times since Nov 28, 2013, and over the history we have for it it has risen 42.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.6566 per EA |
|---|---|
| All-time high | $1.6599 (Jul 15, 2026) |
| All-time low | $1.1296 (Nov 19, 2014) |
| 52-week high | $1.6599 |
| 52-week low | $1.5762 |
| Median price | $1.2338 |
| Average price | $1.3076 |
| Largest weekly change | +5.0% (Jan 10, 2024) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 4 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 94% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
AbbVie Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Levothyroxine Sodium market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
l-Thyroxine class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of SYNTHROID 300 MCG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for SYNTHROID 300 MCG TABLET, manufactured by AbbVie Inc., is $1.6566 per EA (NDC 00074714990), effective Sep 30, 2026.
How has the price of SYNTHROID 300 MCG TABLET changed over time?
Over the history we have for it, the NADAC for SYNTHROID 300 MCG TABLET has risen 42.3%. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for SYNTHROID 300 MCG TABLET?
Since Nov 28, 2013, the NADAC for SYNTHROID 300 MCG TABLET has ranged from a low of $1.1296 (Nov 19, 2014) to a high of $1.6599 (Jul 15, 2026), with a median of $1.2338 per EA.
Are there cheaper alternatives to SYNTHROID 300 MCG TABLET?
Yes. 4 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, LEVOTHYROXINE 300 MCG TABLET, is $0.1043 per EA — about 94% below SYNTHROID 300 MCG TABLET.
Who manufactures SYNTHROID 300 MCG TABLET?
SYNTHROID 300 MCG TABLET (NDC 00074714990) is labeled by AbbVie Inc., and CMS classifies it as a brand product.